Meeting
2016 ASCO Annual Meeting
A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).
Authors
Michael J. Overman
The University of Texas MD Anderson Cancer Center, Houston, TX
Michael J. Overman , Charles D. Lopez , Al Bowen Benson III, Sattva Swarup Neelapu , Niharika B. Mettu , Andrew H. Ko , Vincent M. Chung , John J. Nemunaitis , James Andrew Reeves , Johanna C. Bendell , Philip Agop Philip , Rita Dalal , Maria Fardis , Joy Greer , Xiaolin Wang , Sandeep Inamdar , Brian Joseph Lannutti , Wayne Rothbaum , Raquel Izumi , Milind M. Javle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02362048
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4130)
DOI
10.1200/JCO.2016.34.15_suppl.4130
Abstract #
4130
Poster Bd #
122
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
First Author: Sidharth Puram
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park
Poster
2022 ASCO Annual Meeting
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer